The Coalition will work to improve the quality of life and health of patients with rare diseases.
The Coalition is working to ensure a predictable framework for medical treatment, when such treatment is available. We believe this contributes to improving the quality of life and health of patients with rare diseases. The Coalition currently consists of the biotech companies Amicus, BioMarin, Chiesi and Sanofi.
Since its inception in 2015, the Coalition's aim has been to work to ensure better framework conditions for medical care for patients with rare diseases. The Coalition does this through political participation, external and internal events and through media visibility.
Since its inception, the Coalition has had good cooperation with several actors in the field of rare diseases. On the clinical side, the National Competence Centre for Rare Diagnoses is an important discussion partner, and among the patient organisations, the Norwegian Disabled People's Association (FFO) is important to the Coalition.